JP7543304B2 - 腎臓病の治療のための新規化合物及びその医薬組成物 - Google Patents

腎臓病の治療のための新規化合物及びその医薬組成物 Download PDF

Info

Publication number
JP7543304B2
JP7543304B2 JP2021562854A JP2021562854A JP7543304B2 JP 7543304 B2 JP7543304 B2 JP 7543304B2 JP 2021562854 A JP2021562854 A JP 2021562854A JP 2021562854 A JP2021562854 A JP 2021562854A JP 7543304 B2 JP7543304 B2 JP 7543304B2
Authority
JP
Japan
Prior art keywords
compound
compounds
cyst
acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529814A5 (enExample
JP2022529814A (ja
Inventor
エルス コンラート カーチャ
クリストフ ザビエル ブリス レジナルド
ジャン‐クロード マリー クリストフ ティエリー
バン デール ギースト ロナルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2022529814A publication Critical patent/JP2022529814A/ja
Publication of JP2022529814A5 publication Critical patent/JP2022529814A5/ja
Application granted granted Critical
Publication of JP7543304B2 publication Critical patent/JP7543304B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021562854A 2019-04-24 2020-04-21 腎臓病の治療のための新規化合物及びその医薬組成物 Active JP7543304B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1905711.6 2019-04-24
GBGB1905711.6A GB201905711D0 (en) 2019-04-24 2019-04-24 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
PCT/EP2020/061083 WO2020216740A1 (en) 2019-04-24 2020-04-21 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases

Publications (3)

Publication Number Publication Date
JP2022529814A JP2022529814A (ja) 2022-06-24
JP2022529814A5 JP2022529814A5 (enExample) 2023-04-28
JP7543304B2 true JP7543304B2 (ja) 2024-09-02

Family

ID=66810218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562854A Active JP7543304B2 (ja) 2019-04-24 2020-04-21 腎臓病の治療のための新規化合物及びその医薬組成物

Country Status (16)

Country Link
US (1) US12383544B2 (enExample)
EP (1) EP3958863B1 (enExample)
JP (1) JP7543304B2 (enExample)
KR (1) KR20220004111A (enExample)
CN (1) CN113727711A (enExample)
AU (1) AU2020263869A1 (enExample)
BR (1) BR112021021117A2 (enExample)
CA (1) CA3137445A1 (enExample)
ES (1) ES2982398T3 (enExample)
GB (1) GB201905711D0 (enExample)
IL (1) IL287392A (enExample)
MA (1) MA55752A (enExample)
MX (1) MX2021012544A (enExample)
PH (1) PH12021552680A1 (enExample)
SG (1) SG11202111739VA (enExample)
WO (1) WO2020216740A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096453A1 (en) * 2023-10-30 2025-05-08 Vertex Pharmaceuticals Incorporated Compounds for the treatment of kidney disease
WO2025121320A1 (ja) * 2023-12-04 2025-06-12 国立大学法人山口大学 多発性嚢胞腎の予防又は治療剤
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥（香港）有限公司 用於治療體染色體顯性多囊性腎病之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197911A1 (en) 2004-08-20 2009-08-06 Ingrid Gunda Georg Lonidamine analogues and treatment of polycystic kidney disease
JP2018529743A (ja) 2015-10-09 2018-10-11 アッヴィ・エス・ア・エール・エル Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
JP2018529707A (ja) 2015-10-09 2018-10-11 アッヴィ・エス・ア・エール・エル 嚢胞性線維症の処置のための新規な化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP2464354B1 (en) * 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
TWI633887B (zh) * 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
US10174012B2 (en) * 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
EP3359539A1 (en) 2015-10-09 2018-08-15 AbbVie S.À.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
JP2020525446A (ja) * 2017-06-21 2020-08-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197911A1 (en) 2004-08-20 2009-08-06 Ingrid Gunda Georg Lonidamine analogues and treatment of polycystic kidney disease
JP2018529743A (ja) 2015-10-09 2018-10-11 アッヴィ・エス・ア・エール・エル Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
JP2018529707A (ja) 2015-10-09 2018-10-11 アッヴィ・エス・ア・エール・エル 嚢胞性線維症の処置のための新規な化合物

Also Published As

Publication number Publication date
KR20220004111A (ko) 2022-01-11
SG11202111739VA (en) 2021-11-29
GB201905711D0 (en) 2019-06-05
BR112021021117A2 (pt) 2021-12-14
IL287392A (en) 2021-12-01
JP2022529814A (ja) 2022-06-24
CN113727711A (zh) 2021-11-30
AU2020263869A1 (en) 2021-12-23
PH12021552680A1 (en) 2022-07-04
EP3958863B1 (en) 2024-07-03
CA3137445A1 (en) 2020-10-29
MX2021012544A (es) 2021-11-12
US12383544B2 (en) 2025-08-12
US20220202802A1 (en) 2022-06-30
MA55752A (fr) 2022-03-02
EP3958863C0 (en) 2024-07-03
ES2982398T3 (es) 2024-10-16
EP3958863A1 (en) 2022-03-02
WO2020216740A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
ES2987676T3 (es) Derivado de pirazolopiridina con efecto agonista del receptor de GLP-1
AU2020378407B2 (en) Heterocyclic RIP1 inhibitory compounds
JPWO2007102531A1 (ja) 併用薬
UA128751C2 (uk) Інгібітори rip1k
JP2021534259A (ja) ＪＡＫ阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン化合物およびその使用
MD3788045T2 (ro) Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
EA020681B1 (ru) Циклические n,n'-диарилтиомочевины и n,n'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения
US12383544B2 (en) Methods for the treatment of polycystic kidney disease
JP2017516821A (ja) ナフチリジンジオン誘導体
EP3383851B1 (en) Dextrorphan-derivatives with suppressed central nervous activity
EA017117B1 (ru) 2-АМИНО-3-СУЛЬФОНИЛТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИДОПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT-РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US10166236B2 (en) Pharmaceutical formulations comprising substituted pyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazines for treating lysosomal storage disorders
CN109422753A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
CN109422751B (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
EA017817B1 (ru) 3-АРИЛСУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
SG11202111877TA (en) Method for treating cough by using diaminopyrimidine compound
EA017630B1 (ru) ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT-РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EA018944B1 (ru) Замещенные 8-сульфонил-2,3,4,5-тетрагидро-1н-гамма-карболины, лиганды, фармацевтическая композиция, способ их получения и применения
WO2024013567A1 (en) Biaryl ether urea compounds as faah inhibitors
CN106795160A (zh) 取代的吲哚化合物及其使用方法和用途
WO2025104491A1 (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
EP2488528A1 (en) Pyrrolo [3,2 -e][1,2,4]triazolo [1,5-a]pyrimidines derivatives as inhibitors of microglia activation
BR112019026430B1 (pt) Composto de tetrahidropiridopirazina ou seus sais aceitáveis, composição comprendendo o mesmo, combinação, e seu uso no tratamento de doença relacionada ao gpr6

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240821

R150 Certificate of patent or registration of utility model

Ref document number: 7543304

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150